Austrianova Biotechnology
Singapore, Singapore· Est.
Austrianova delivers a patented cell‑encapsulation platform for immune‑protected, off‑the‑shelf cell and probiotic therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Austrianova delivers a patented cell‑encapsulation platform for immune‑protected, off‑the‑shelf cell and probiotic therapies.
OncologyImmunologyRegenerative MedicineInfectious DiseasesAnti-Aging
Technology Platform
Proprietary cellulose‑sulphate encapsulation (Cell‑in‑a‑Box® / Bac‑in‑a‑Box®) that protects living cells or microbes, allows in‑capsule growth, and enables long‑term cryostorage and immune‑isolated delivery.
Opportunities
Licensing the Cell‑in‑a‑Box® platform to pharma partners and expanding the Klotho anti‑aging pipeline could drive significant revenue growth.
Risk Factors
Regulatory approval timelines for encapsulated cell therapies and competition from alginate‑based platforms pose key execution risks.
Competitive Landscape
Few companies offer cellulose‑sulphate encapsulation; Austrianova differentiates itself from alginate‑based rivals through superior storage stability and immune‑inert properties.